NEXTECH INVEST LTD
Q4 2021 Form 13-F

ZURICH
CIK 0001911010 · CRD 322629 · Exempt reporting adviser
$379.6M Reported Value Total
Exempt Reporting Adviser
Source: Form ADV filed 2026-03-27
Reported value
$379.6M
Quarter over quarter
0.0%
Holdings
11
Top-10 concentration
98.0%

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Marco Weibel
Chief Financial Officer

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2021 13F record

Q4 2021 13F filing summary

Q4 2021 Form 13F portfolio summary
Period of report December 31, 2021
Filed February 14, 2022
Form 13F-HR
Reported value $379.6M
Positions 11
Change in reported value First reported quarter
Top-10 concentration 98.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q4 2024 13F
Filed Feb 14, 2025
15 $616.4M
Q3 2024 13F
Filed Nov 14, 2024
15 $712.3M
Q2 2024 13F
Filed Aug 14, 2024
13 $594.5M
Q1 2024 13F
Filed May 15, 2024
12 $630.8M
Q4 2023 13F
Filed Feb 14, 2024
11 $536.8M
Q3 2023 13F
Filed Nov 14, 2023
14 $330.0M
Q2 2023 13F
Filed Aug 14, 2023
13 $294.2M
Q1 2023 13F
Filed May 12, 2023
12 $239.6M
Q4 2022 13F
Filed Feb 14, 2023
14 $251.4M
Q3 2022 13F
Filed Nov 14, 2022
14 $309.6M
Q2 2022 13F
Filed Aug 1, 2022
14 $296.5M
Q1 2022 13F
Filed May 16, 2022
14 $350.3M
Q4 2021 13F
Filed Feb 14, 2022
11 $379.6M

Top 11 holdings · Q4 2021

Largest Q4 2021 13F positions by reported value
# Holding Reported value % of portfolio
1 EQRX EQRX INC $89.4M 23.55%
2 RVMD REVOLUTION MEDICINES INC $74.7M 19.68%
3 KNTE KINNATE BIOPHARMA INC $53.3M 14.04%
4 TYRA TYRA BIOSCIENCES INC $35.4M 9.34%
5 PMVP PMV PHARMACEUTICALS INC $32.0M 8.43%
6 ARVN ARVINAS INC $23.6M 6.22%
7 KRON KRONOS BIO INC $19.7M 5.2%
8 CGEM CULLINAN ONCOLOGY INC $18.8M 4.96%
9 SPRY SILVERBACK THERAPEUTICS INC $12.7M 3.35%
10 CCCC C4 THERAPEUTICS INC $12.1M 3.19%
11 THRX THESEUS PHARMACEUTICALS INC $7.8M 2.04%

Values as reported on the Q4 2021 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings